7 analysts have shared their evaluations of CG Oncology (NASDAQ:CGON) during the recent three months, expressing a mix of bullish and bearish perspectives.

The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $68.14, along with a high estimate of $75.00 and a low estimate of $61.00. Marking an increase of 14.71%, the current average surpasses the previous average price target of $59.40.

Understanding Analyst Ratings: A Comprehensive Breakdown

The standing of CG Oncology among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

For valuable insights into CG Oncology's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on CG Oncology analyst ratings.

Get to Know CG Oncology Better

CG Oncology's Economic Impact: An Analysis

Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.

Revenue Growth: CG Oncology's revenue growth over a period of 3M has been noteworthy. As of 30 September, 2025, the company achieved a revenue growth rate of approximately 3774.42%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: CG Oncology's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -2629.53%, the company may face hurdles in effective cost management.

Return on Equity (ROE): CG Oncology's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -6.45%, the company may face hurdles in achieving optimal financial returns.

Return on Assets (ROA): CG Oncology's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -6.12%, the company may face hurdles in achieving optimal financial returns.

Debt Management: CG Oncology's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

Analyst Ratings: What Are They?

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.

This article was generated by Benzinga's automated content engine and reviewed by an editor.